Track record · closed signal

Abbott Laboratories (ABT) — closed signal from February 1, 2026

Partial Published before the outcome was known, scored automatically when the window closed on May 2, 2026.

Predicted vs. what happened

ABT price · publication thesis → realized outcomesplit-adjusted

$106.00 – $110.50Entry zone — fair-value band

$109.30Published — price the day we called it

$122.42Target — the price the thesis aimed for

$116.82Peak — highest point inside the window, not a realized return

$89.46Window close — end-of-window price, context only

What happened

Partial

Reached 58% of the predicted growth at its peak, without hitting the target.

Peak price

$116.82

peak on February 27, 2026 — not a realized return

Peak gain

+6.9%

peak, from the publication price

Window close

$89.46

end-of-window price, context only

Days to target

—

Window

February 1, 2026 – May 2, 2026

The thesis — published February 1, 2026

Predicted growth

+12%

over the measurement window

Target price

$122.42

the price the thesis aimed for

Entry zone

$106.00 – $110.50

the fair-value band we waited for

Price at publication

$109.30

published February 1, 2026

Confidence

69%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Abbott could get a boost from buying Exact Sciences to grow its cancer testing business, and the CEO buying shares plus a recent upgrade help improve sentiment. After a weak period this could be a short rebound over 0-3 months. Only buy on controlled dips near the support band because the stock still needs to settle.

Primary drivers

Buying Exact Sciences would expand its cancer testing business
CEO buying shares and an upgrade make investors more confident
Shifting its portfolio can reduce worries about Nutrition weakness
Stock still needs to settle, so treat as a short-term rebound

How it played out

ABT: target missed after a partial rebound

Lyra published ABT on 2026-02-01 at 109.3 with expected growth of 12% and a target of 122.42. The thesis pointed to the Exact Sciences deal, CEO share buying, an upgrade, portfolio changes, and a possible short-term rebound after a weak period.

Inside the window, ABT rose to 116.82 on 2026-02-27, a 6.9% peak gain. That stayed below the target. It never got there. By the end of the window it was at 89.46. The thesis partly played out early, then missed by the close.

What happened during the window

On April 16, 2026, Investor's Business Daily reported that Abbott posted first-quarter adjusted earnings of $1.15 on sales of $11.16 billion and lowered its 2026 earnings outlook after the Exact Sciences acquisition. On the same date, The Wall Street Journal reported that Abbott said a weaker flu season hurt recent sales and that the Exact Sciences deal was expected to reduce adjusted earnings for the year.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All ABT signals